慢性複雑性尿路感染症に対するTicarcillin (TIPC) の基礎的, 臨床的検討

DOI Web Site

書誌事項

タイトル別名
  • LABORATORY AND CLINICAL EVALUATIONS OF TICARCILLIN IN CHRONIC COMPLICATED URINARY TRACT INFECTIONS
  • マンセイ フクザツセイ ニョウロ カンセンショウ ニ タイスル Ticarci

この論文をさがす

抄録

1. Antibacterial spectrum of ticarcillin is almost similar with that of CBPC and SBPC against gram negative rod. But, ticarcillin showed 2-4 times superior results as to Pseudomonas in antibacterial activity.<BR>2. Absorption and excretion were compared in healthy volunteers and in renal normal patients and in renal impaired ones. The peak of serum concentration following intravenous injection was just after administration, thereafter, fell rapidly and disappeared after 4-6 hours. The urinary recovery rate was approximately 70-90% till 6 8 hours, The renal impaired patients showed slow excretion, high serum concentration, slow fall and low urinary recovery rate.<BR>3. Ticarcillin was administered to 22 patients with urinary tract infection. Two acute uncomplicated urinary tract infections showed an excellent result within 4 days of therapy. The effective rate was 60% (9/15) in 15 chronic complicated U. T. I. excluding 5 superinfections. In 12 cases caused by Pseudomonas, the effective rate was 85. 7% (6/7) excluding 5 superinfections (excellent; 5, good; 1, poor; 1, superinfection; 5) on causative organisms. Four cases caused by Klebsiella showed poor response. The daily dose was 4. 0 g-6.0 g excluding one case with bacteremia.<BR>4. Bacteremia caused by Pseudomonas was cured by daily dose of 12. 0 g of ticarcillin and that of 200 mg of DKB.<BR>5. Four increased values of GOT and one of GPT were noticed in liver function in 20 cases. But, these increased values were all slight and returned to normal values within 2 weeks after discontinuance of administration. No abnormal findings were seen in renal function and blood chemistry.<BR>6. Ticarcillin showed good response in U. T. I. caused by Pseudomonas and Proteus spp. So, ticarcillin can be expected the same or more response at a half dose compared with CBPC and SBPC in these infections.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ